Skip to content

Indole-based peptidomimetic maleimides as SARS-CoV-2 Mpro inhibitor scaffolds compatible with reversible covalent inhibition: Warhead optimization and broad in vitro antiviral activity.

Sep 2026 · Bioorganic chemistry (Print) · Vol 183, pp. 110561 · 0 citations · 58 references
Medicine

TL;DR

Indole-based peptidomimetic maleimides are identified as chemically tractable Mpro inhibitor scaffolds with a binding mode compatible with reversible covalent inhibition and support compound 8i as a lead for further antiviral optimization.

Abstract

Although several SARS-CoV-2 main protease (Mpro) inhibitors have been clinically authorized, the continued evolution of SARS-CoV-2 and the emergence of resistance-associated mutations highlight the need for additional inhibitor scaffolds with balanced potency, chemical stability, and reversible covalent reactivity. Herein, we report the discovery and warhead optimization of indole-based peptidomimetic maleimides as Mpro inhibitor scaffolds with a binding mode compatible with reversible covalent inhibition. Initial attempts to access α-cyanoacrylate analogues afforded product-related fractions whose chromatographic and mass-spectrometric profiles changed during purification and analytical handling, preventing isolation of analytically pure samples for biological profiling. DFT calculations showed higher electrophilicity for the α-cyanoacrylate model and provided a supportive electronic rationale for the contrasting purification and handling behavior of the two warhead classes. Subsequent optimization of the maleimide series identified compound 8i as the lead inhibitor, with single-digit nanomolar inhibition of wild-type Mpro (IC50 = 6.51 nM). Jump-dilution experiments supported a reversible binding component compatible with a reversible covalent inhibition mode. In P-gp inhibitor-supplemented Vero E6 CPE assays, 8i showed broad in vitro antiviral activity against wild-type, Delta, and Omicron BA.5 SARS-CoV-2 variants, with EC50 values of 1.44, 0.49, and 1.52 μM, respectively, while 50% cytotoxicity was not reached at concentrations up to 100 μM under the applied assay conditions. Covalent docking and 100 ns molecular dynamics simulations were used to provide supportive structural interpretations of the modeled Mpro complexes and to compare compound 8i with the less active N-substituted analogue 8g. Because biochemical activity against the selected mutant proteases has not been experimentally determined, the docking results should be interpreted as hypothesis-generating structural models rather than evidence of mutation tolerance. Overall, these findings identify indole-based peptidomimetic maleimides as chemically tractable Mpro inhibitor scaffolds with a binding mode compatible with reversible covalent inhibition and support compound 8i as a lead for further antiviral optimization.

View source

Similar papers

Nov 2026

Discovery and Mechanistic Characterization of Tetrahydroisoquinoline Derivatives as Inhibitors of SARS‐CoV‐2 Main Protease

SARS‐CoV‐2 main protease (Mpro) is an enzyme for viral replication and an target for antiviral drugs due to its evolutionary conservation across coronaviruses and the absence of closely related human homologs. Tetrahydroisoquinoline (THIQ) derivatives represent a structurally diverse class of nitrogen‐containing hete...

Wen-Hui Zhang, Nuo-Ya Wang, Wen-Jing Yu et al. · 0 citations
Open access Oct 2026

Evaluation of 6-substituted coumarins as SARS-CoV-2 main protease inhibitors: enzymatic, cellular, and computational insights

The SARS-CoV-2 main protease (Mpro) plays a crucial role in viral replication, making it an attractive target for antiviral drug development. This study evaluates the inhibitory potential of nineteen 6-substituted coumarin derivatives (1a–p and 2a–c) against Mpro using a FRET-based enzymatic assay. Among them, the chlo...

Ashraf K. El-Damasy, Md Sofequl Islam Mukim, Sangeun Jeon et al. · 0 citations
2027

Synthesis, crystal structure, pharmacophore analysis and molecular docking of monoterpene-isatin conjugates as potential SARS-CoV-2 PLpro ligands with in vitro antiviral evaluation

A series of novel conjugates combining monoterpenoid fragments (camphor, fenchone) with an isatin scaffold was designed as potential SARS-CoV-2 PLpro inhibitors. Molecular docking and pharmacophore analysis confirmed their ability to bind to the active site of PLpro. Single crystal of target compound 12 was grown, the...

V. V. Oreshko, S. Borisevich, K. Kovaleva et al. · 0 citations
Oct 2026

Discovery of Epoxysuccinates as Potent Covalent Inhibitors of SARS-CoV-2 Papain-like Protease.

The papain-like protease (PLpro) of SARS-CoV-2, essential for viral processing and immune evasion, is a promising therapeutic target for coronavirus infections. Incorporating strategies used to enhance activity of non-covalent inhibitors, notably engagement of the BL2-groove, remote from the active site Cys-111, covale...

Farinaz Soleymani, Ganga Reddy Velma, Zheng-Nan Shen et al. · 0 citations
Oct 2026

Integrating in vitro and in silico correlation of thiazole-based carboxamide derivatives as promising SARS-CoV-2 papain-like protease inhibitors: a versatile approach for COVID-19 therapy

Experimental and computational findings identify thiazole-based carboxamide derivatives, particularly compounds (8) and (6), as promising candidates for the development of potent SARS-CoV-2 PLpro inhibitors.

Imran Khan, Rafaqat Hussain, H. Sarfraz et al. · 0 citations
Open access Sep 2026

Repurposing Thiazole/Benzothiazole-Based Thiazolidinone Derivatives as SARS-CoV-2 Main Protease (Mpro) Inhibitors: An Integrated Computational and Experimental Study

Background/Objectives: SARS-CoV-2, the causative agent of COVID-19, relies on its main protease (Mpro) for viral replication, making this enzyme an attractive target for antiviral drug development. In the present study, we investigated whether a library of previously synthesized thiazole/benzothiazole-based thiazolidin...

A. Petrou, Aliki Papadimitriou-Tsantarliotou, Hathaichanok Chuntakaruk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.